- In March 2024, DNDi and Bayer AG are jointly assessing emodepside as a potential macrofilaricidal treatment for human onchocerciasis. This collaboration positions Bayer as a key innovator in addressing neglected tropical diseases, enhancing its reputation and expanding its portfolio in global health solutions
- In May 2021, MDP and Merck pledged USD 500,000 to enhance laboratory capacity for onchocerciasis elimination in Africa, in collaboration with WHO’s diagnostics center at the University of South Florida. This initiative strengthens Merck’s corporate social responsibility profile, showcasing its commitment to combating neglected tropical diseases and fostering goodwill in global health initiatives
Frequently Asked Questions
The market is segmented based on Segmentation, By Drug Type (Ivermectin, Doxycycline, Albendazole, and Moxidectin), Mode of Administration (Oral, Injectables, and Topical), Treatment Strategy (Mass Drug Administration (MDA) and Targeted Treatment), End-User (Hospitals & Clinics, Home Care Settings, and Government & Non-Governmental Programs), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) – Industry Trends and Forecast to 2032
.
The Global Onchocerciasis Treatment Market size was valued at USD 589.52 USD Million in 2024.
The Global Onchocerciasis Treatment Market is projected to grow at a CAGR of 8.78% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, Rest of South America.
